Date: 2015-11-09
Type of information: Nomination
Compound:
Company: Strongbridge Biopharma (Ireland)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 4, 2015, Strongbridge Biopharma, formerly known as Cortendo, announced that Matthew Pauls, president and chief executive officer of Strongbridge Biopharma plc, has been appointed to the Company’s Board of Directors. Mr. Pauls’s appointment as a director is effective immediately. The Company also announced that Eigil Stray Spetalen, who has served as a director and previously as chairman of Cortendo AB, has elected to step down from the Cortendo AB Board of Directors. Mr. Pauls has served as president and chief executive officer of Cortendo AB since August 2014. Prior to joining Cortendo AB, Mr. Pauls was chief commercial officer of Insmed, Inc., responsible for the development of the global commercial strategy and technical operations for an inhaled therapy for rare lung diseases. Prior to Insmed, Mr. Pauls served as senior vice president, head of global commercial operations at Shire Pharmaceuticals and also held senior positions at Bristol-Myers Squibb in brand management and payor marketing, and at Johnson & Johnson in various U.S. and global commercial roles. Mr. Pauls is a volunteer board member of the Pennington School in Pennington, New Jersey, and the Boys & Girls Clubs of Philadelphia. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law. Following the settlement of its exchange offer to acquire any and all issued ordinary shares of Cortendo AB, Strongbridge Biopharma is now the new parent company of the Cortendo group.
Financial terms:
Latest news:
